Dissection of the Superior Mesenteric Artery Clinical Trial
Official title:
Safety and Effectiveness of Endovascular Stent Therapy in Patients With Dissection of the Superior Mesenteric Artery: a Multicenter, Prospective Observational Study
This study aims to evaluate the prognosis of patients with spontaneous solitary dissection of superior mesenteric artery (SIDSMA) who have been treated with stents.
This study is an observational study. The subject's treatment plan needs to be expected to meet the following conditions: the corresponding surgery has been completed: the femoral artery or brachial artery approach is implanted into the true lumen of the SMA bare stent (the part with a diameter ≤ 7mm is above the 100-strong stent, and the part with a diameter> 7mm It is not limited to using stents (brands) to restore the real lumen blood flow of the superior mesenteric artery. If the false cavity is large, it can be combined with a spring coil to assist embolization. Anticoagulation therapy for at least 1 day after surgery, anticoagulation drugs are not limited to use, and discharge After taking the double antibody for 3 months, the monoclonal antibody should be maintained for at least 1 year. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03916965 -
Stent Implantation for Patients With SIDSMA
|